org/ 10. 1186/ s12967- 022- 03624-z. Additional file 1: Table S1. Samples selected for TCR sequencing. Table S2. Biopsies used for immunofluorescence staining. Table S3. Antibodies and amplification reagents used for multiplex fluorescence IHC. Figure S1. Comparison of mutations in baseline and post-treatment biopsy. Figure S2. Baseline HLA class I and II expression in clinical responders vs. non-responders. Figure S3. Vaccine-enriched TCRs. Figure S4. Gene expression profiles at baseline vs. post-treatment. Figure S5. Gene set enrichment analysis of differentially expressed genes post-treatment. Acknowledgements Not applicable. Author contributions Conception and design: EBE, GG, TG. Development of methodology: EBE, GB, IK, IA, DS, TC, AM, EMI, SMM, MB, EH, GG. Acquisition, analysis, and interpreta- tion: EBE, GB, IK, IA, DS, AM, GG, and all authors. Writing: EBE and all authors. All authors read and approved the final manuscript. Funding The UV1/hTERT-MM trial was sponsored by Ultimovacs ASA (Oslo, Norway). This project received funding from the Norwegian Research Council (grant number 298864) and Eurostars (grant number 284619). Availability of data and materials Relevant data are provided in the publication and supplementary material. Further details are available on reasonable request. Whole-exome sequenc- ing data are deposited in the European Genome-Phenome Archive (https:// ega- archi ve. org/) under accession number EGAS00001005253. The requests to access the dataset should be directed at espen.ellingsen@ultimovacs.com.Declarations Ethics approval and consent to participate The study participants provided written informed consent prior to enrolment. The trial was conducted in accordance with the ethical principles of the Decla- ration of Helsinki and the International Conference on Harmonization of Good Clinical Practice and approved by an independent ethics committee and the appropriate national and institutional review boards (REK reference 2014/421). Consent for publication Not applicable. Competing interests EBE, SMM, and GG are employees of Ultimovacs ASA or Ultimovacs AB. GG, SMM, and EMI are shareholders in Ultimovacs ASA. GG and EMI are inventors of the UV1 patent. SMM is the founder and shareholder of Immuneed AB, Vivologica AB, and Strike Pharma AB, none of which has had any role in this work. Other authors declare that they have no conflicts of interest. Author details 1 Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway. 2 Faculty of Medicine, University of Oslo, Oslo, Norway. 3 Ultimovacs ASA, Oslo, Norway. 4 ENPICOM B.V., DA ’s-Hertogenbosch, Netherlands. 5 Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. 6 NEC Oncoimmunity, Oslo, Norway. 7 Department for Internal Medicine IV - Hematology and Oncology, Universitätsklinikum Halle (Saale), Halle, Germany. 8 Department of Oncology, Oslo University Hos- pital, Oslo, Norway. 9 HistoOne AB, Uppsala, Sweden. 10 Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway. 11 Ultimovacs AB, Uppsala, Sweden. 12 Centre for Bioinformatics, University of Oslo, Oslo, Norway. Received: 10 August 2022 Accepted: 1 September 2022 References 1.